JP2016525600A - シクロデキストリン - Google Patents
シクロデキストリン Download PDFInfo
- Publication number
- JP2016525600A JP2016525600A JP2016526700A JP2016526700A JP2016525600A JP 2016525600 A JP2016525600 A JP 2016525600A JP 2016526700 A JP2016526700 A JP 2016526700A JP 2016526700 A JP2016526700 A JP 2016526700A JP 2016525600 A JP2016525600 A JP 2016525600A
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- sbe
- substitution
- reaction
- ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361847509P | 2013-07-17 | 2013-07-17 | |
| GBGB1312737.8A GB201312737D0 (en) | 2013-07-17 | 2013-07-17 | Cyclodextrin |
| GB1312737.8 | 2013-07-17 | ||
| US61/847,509 | 2013-07-17 | ||
| PCT/GB2014/052173 WO2015008066A1 (en) | 2013-07-17 | 2014-07-16 | Cyclodextrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525600A true JP2016525600A (ja) | 2016-08-25 |
| JP2016525600A5 JP2016525600A5 (https=) | 2016-10-06 |
Family
ID=49081370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526700A Pending JP2016525600A (ja) | 2013-07-17 | 2014-07-16 | シクロデキストリン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11117978B2 (https=) |
| EP (1) | EP3022231B1 (https=) |
| JP (1) | JP2016525600A (https=) |
| KR (1) | KR20160031019A (https=) |
| CN (1) | CN105431458A (https=) |
| AP (1) | AP2016008975A0 (https=) |
| AU (1) | AU2014291800A1 (https=) |
| CA (1) | CA2919501A1 (https=) |
| CL (1) | CL2016000082A1 (https=) |
| GB (3) | GB201312737D0 (https=) |
| HU (1) | HUE038911T2 (https=) |
| MX (1) | MX2016000553A (https=) |
| PT (1) | PT3022231T (https=) |
| WO (1) | WO2015008066A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| WO2018140856A1 (en) | 2017-01-30 | 2018-08-02 | Bio-Rad Laboratories, Inc. | Emulsion compositions and methods of their use |
| WO2018146698A1 (en) | 2017-02-07 | 2018-08-16 | Biophore India Pharmaceuticals Pvt. Ltd. | Improved method for the preparation of sulfobutylether beta cyclodextrin sodium |
| CN112557541B (zh) * | 2020-12-08 | 2022-07-12 | 河北科技大学 | 一种枸橼酸马罗匹坦及其有关物质的检测方法 |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
| CN114369177A (zh) * | 2021-12-31 | 2022-04-19 | 贵州省欣紫鸿药用辅料有限公司 | 一种采用管道反应器制备磺丁基醚-β-环糊精的方法 |
| WO2025229196A1 (en) | 2024-05-03 | 2025-11-06 | Aalborg Universitet | Primary side modified sulfoalkyl ether- and hydroxypropyl-cyclodextrins, synthesis and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| ES2257795T3 (es) * | 1997-07-01 | 2006-08-01 | Pfizer Products Inc. | Procedimiento para producir una ciclodextrina. |
| US6337380B1 (en) * | 1998-12-01 | 2002-01-08 | Fuji Photo Film Co., Ltd. | Polymer having sulfonic acid group and silver halide photographic photosensitive material using the polymer |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| CN100503647C (zh) | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
| CN101686681B (zh) * | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| DK3702374T3 (da) * | 2012-02-15 | 2022-06-27 | Cydex Pharmaceuticals Inc | Fremsgangsmåde til fremstilling for cyclodextrin-derivater |
| PH12012502259A1 (en) | 2012-05-08 | 2019-07-03 | Onyx Therapeutics Inc | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
-
2013
- 2013-07-17 GB GBGB1312737.8A patent/GB201312737D0/en not_active Ceased
-
2014
- 2014-07-16 HU HUE14742322A patent/HUE038911T2/hu unknown
- 2014-07-16 GB GB1412644.5A patent/GB2519832B/en active Active
- 2014-07-16 JP JP2016526700A patent/JP2016525600A/ja active Pending
- 2014-07-16 CN CN201480040709.2A patent/CN105431458A/zh active Pending
- 2014-07-16 AP AP2016008975A patent/AP2016008975A0/xx unknown
- 2014-07-16 EP EP14742322.2A patent/EP3022231B1/en active Active
- 2014-07-16 CA CA2919501A patent/CA2919501A1/en not_active Abandoned
- 2014-07-16 AU AU2014291800A patent/AU2014291800A1/en not_active Abandoned
- 2014-07-16 WO PCT/GB2014/052173 patent/WO2015008066A1/en not_active Ceased
- 2014-07-16 PT PT147423222T patent/PT3022231T/pt unknown
- 2014-07-16 US US14/333,417 patent/US11117978B2/en active Active
- 2014-07-16 KR KR1020167003973A patent/KR20160031019A/ko not_active Withdrawn
- 2014-07-16 GB GB2015609.7A patent/GB2586104B/en active Active
- 2014-07-16 MX MX2016000553A patent/MX2016000553A/es unknown
-
2015
- 2015-09-30 US US14/871,649 patent/US10239961B2/en active Active
-
2016
- 2016-01-14 CL CL2016000082A patent/CL2016000082A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2519832A (en) | 2015-05-06 |
| GB201312737D0 (en) | 2013-08-28 |
| WO2015008066A1 (en) | 2015-01-22 |
| EP3022231B1 (en) | 2018-04-18 |
| AP2016008975A0 (en) | 2016-01-31 |
| GB2586104A (en) | 2021-02-03 |
| AU2014291800A1 (en) | 2016-02-11 |
| CN105431458A (zh) | 2016-03-23 |
| HUE038911T2 (hu) | 2018-12-28 |
| GB201412644D0 (en) | 2014-08-27 |
| US20160024229A1 (en) | 2016-01-28 |
| GB202015609D0 (en) | 2020-11-18 |
| US10239961B2 (en) | 2019-03-26 |
| MX2016000553A (es) | 2016-08-01 |
| US11117978B2 (en) | 2021-09-14 |
| GB2519832B (en) | 2021-03-03 |
| KR20160031019A (ko) | 2016-03-21 |
| US20150025023A1 (en) | 2015-01-22 |
| EP3022231A1 (en) | 2016-05-25 |
| CL2016000082A1 (es) | 2016-09-23 |
| CA2919501A1 (en) | 2015-01-22 |
| GB2586104B (en) | 2021-03-31 |
| PT3022231T (pt) | 2018-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525600A (ja) | シクロデキストリン | |
| Sarabia-Vallejo et al. | Cyclodextrin inclusion complexes for improved drug bioavailability and activity: synthetic and analytical aspects | |
| JP6508944B2 (ja) | シクロデキストリン誘導体のための製造方法 | |
| Spiridon et al. | Cyclodextrins as multifunctional platforms in drug delivery and beyond: structural features, functional applications, and future trends | |
| Yuan et al. | Evaluation of complex forming ability of hydroxypropyl-β-cyclodextrins | |
| Adeoye et al. | Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: In silico prediction; Effects of derivatization, molar ratio and preparation method | |
| Kono et al. | Elucidation of substituent distribution states for carboxymethyl chitosan by detailed NMR analysis | |
| CN108778338A (zh) | 活性药物成分的连续络合 | |
| Arshad et al. | Microwave-assisted, sulfhydryl-modified β-cyclodextrin-silymarin inclusion complex: A diverse approach to improve oral drug bioavailability via enhanced mucoadhesion and permeation | |
| Wang et al. | Physicochemical properties and mechanism of solubilised neohesperidin system based on inclusion complex of hydroxypropyl-β-cyclodextrin | |
| Nan et al. | An economic, accessible and stable sulphated cyclodextrin polymer as selector for efficiently separating chiral drugs in HPLC | |
| Tongiani et al. | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives, their synthesis, NMR characterization, and binding of 6α-methylprednisolone | |
| Fürst et al. | Mucoadhesive polymers: Design of S-protected thiolated cyclodextrin-based hydrogels | |
| CN107574198B (zh) | 一种采用醇沉分级制备螺旋糊精包结络合载体的方法 | |
| CN105143274A (zh) | 糖原基水溶性增强剂 | |
| Volkova et al. | Cyclodextrin effects on the distribution, solubility and transport properties of umifenovir | |
| EP2736614B1 (en) | Method of removing alkylene halogenohydrin from cellulose ether | |
| Savage et al. | Continuous tank reactor synthesis of highly substituted sulphobutylether β-cyclodextrins | |
| Yudiarto et al. | Separation of structural isomers using soluble β-cyclodextrin polymer by ultrafiltration | |
| Savage et al. | Cyclodextrin | |
| Gorshkova et al. | Water-soluble modified chitosan and its interaction with a polystyrenesulfonate anion | |
| CN101224298B (zh) | 一种丙泊酚组合物 | |
| US8865887B2 (en) | Method for synthesizing calixarene and/or cyclodextrin copolymers, terpolymers and tetrapolymers, and uses thereof | |
| CN101590029A (zh) | 一种丙泊酚组合物 | |
| FR2954771A1 (fr) | Nouveau procede de synthese de copolymeres, terpolymeres et tetrapolymeres de cyclodextrines et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160712 |